Geovax Labs Inc (GOVX)
$1.46
Insights on Geovax Labs Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 129.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 340.0%
Performance
- $1.45$1.68$1.46
0.68%
Downside
Day's Volatility :13.69%
Upside
13.1%
- $1.46$11.54$1.46
0.0%
Downside
52 Weeks Volatility :87.35%
Upside
87.35%
Returns
| Period | Geovax Labs Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -68.42% | -0.5% | 0.0% |
6 Months | -81.08% | 5.9% | 0.0% |
1 Year | -84.99% | 3.1% | -1.9% |
3 Years | -97.72% | 14.2% | -21.8% |
Highlights
Market Capitalization | 3.6M |
Book Value | $2.92 |
Earnings Per Share (EPS) | -14.29 |
PEG Ratio | 0.0 |
Wall Street Target Price | 76.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -82.27% |
Return On Equity TTM | -160.47% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 81.5K |
EBITDA | -26.7M |
Diluted Eps TTM | -14.29 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.56 |
EPS Estimate Next Year | -3.96 |
EPS Estimate Current Quarter | -2.78 |
EPS Estimate Next Quarter | -3.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 5122.6%
Technicals Summary
Sell
Neutral
Buy
Geovax Labs Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Geovax Labs Inc | -19.05% | -81.08% | -84.99% | -97.72% | -96.53% |
 Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
 Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
 Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
 Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Geovax Labs Inc | NA | NA | 0.0 | -6.56 | -1.6 | -0.82 | NA | 2.92 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Geovax Labs Inc | Buy | $3.6M | -96.53% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Institutional Holdings
Vanguard Group Inc
2.24%BlackRock Inc
1.27%Geode Capital Management, LLC
0.53%State Street Corporation
0.30%Morgan Stanley - Brokerage Accounts
0.15%Northern Trust Corp
0.11%
Company Information
geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.
Organization | Geovax Labs Inc |
Employees | 17 |
CEO | Mr. David Alan Dodd |
Industry | Biotechnology |
